High Endothelial Venule with Concomitant High CD8+ Tumor-Infiltrating Lymphocytes Is Associated with a Favorable Prognosis in Resected Gastric Cancer

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Aug 23

PMID 32823631

Citations 20

Authors

Soon Auck Hong

Hye Won Hwang

Min Kyoon Kim

Tae Jin Lee

Kwangil Yim

Hye Sung Won

DER Sheng Sun

Eun Young Kim

Yoon Ho Ko

Affiliations

Soon will be listed here.

Abstract

CD8+ tumor-infiltrating lymphocytes (TILs) play a major role in antitumor immunity. High endothelial venules (HEVs) are related to diverse immune cells in solid tumors. We analyzed CD8+ and Foxp3+ TILs in combination with HEVs to determine their prognostic role in advanced gastric cancer (AGC). We enrolled 157 patients with AGC in this study. The densities of CD8+ TILs and Foxp3+ TILs were calculated using immunohistochemical staining. HEVs were evaluated by MECA-79 expression. HEVs were identified in 60 (38.2%) cases and was significantly associated with an increased number of CD8+ TILs ( = 0.027) but not of Foxp3+ TILs ( = 0.455) and CD20+ TILs ( = 0.163). A high CD8+/HEV+ level was significantly associated with nodal metastasis ( = 0.048). In survival analysis, patients with high CD8+/HEV+ levels demonstrated the longest overall survival (OS) ( = 0.015). Furthermore, a high CD8+/HEV+ level was an independent prognostic factor in AGC ( = 0.011; hazard ratio (HR) = 0.435; 95% confidence interval (CI) = 0.245-0.837). HEVs were found to play an important role in antitumor immunity associated with CD8+ TILs in AGC. This analysis of HEVs and CD8+ TILs helps stratify patients with AGC and sheds light on tumor immunity.

Citing Articles

Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer.

Chen W, Zhang L, Gao M, Zhang N, Wang R, Liu Y Front Immunol. 2025; 15():1519034.

PMID: 39840050 PMC: 11747648. DOI: 10.3389/fimmu.2024.1519034.

Prognostic Significance of CD11b-, CD8-, and CD163-Positive Tumor-Infiltrating Immune Cells in Distal Bile Duct Cancer.

Choi J, Kim J, Lee K, Lee G, Hong M, Hwang H J Pers Med. 2024; 14(10).

PMID: 39452540 PMC: 11508419. DOI: 10.3390/jpm14101033.

Recent clinical researches and technological development in TIL therapy.

Matsueda S, Chen L, Li H, Yao H, Yu F Cancer Immunol Immunother. 2024; 73(11):232.

PMID: 39264449 PMC: 11393248. DOI: 10.1007/s00262-024-03793-4.

Intratumoral high endothelial venules in solid tumors: a pooled study.

Wang B, Han Y, Liu J, Zhang X, Deng Y, Jiang Y Front Immunol. 2024; 15:1401118.

PMID: 39040120 PMC: 11260642. DOI: 10.3389/fimmu.2024.1401118.

Mapping the complexity and diversity of tertiary lymphoid structures in primary and peritoneal metastatic gastric cancer.

Groen-van Schooten T, Franco Fernandez R, van Grieken N, Bos E, Seidel J, Saris J J Immunother Cancer. 2024; 12(7).

PMID: 38955417 PMC: 11218001. DOI: 10.1136/jitc-2024-009243.

References

Bai X, Liu J, Li O, Zheng P, Liu Y . Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest. 2003; 111(10):1487-96. PMC: 155049. DOI: 10.1172/JCI17656. View

Ager A, May M . Understanding high endothelial venules: Lessons for cancer immunology. Oncoimmunology. 2015; 4(6):e1008791. PMC: 4485764. DOI: 10.1080/2162402X.2015.1008791. View

Zhang Y, Huang S, Gong D, Qin Y, Shen Q . Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010; 7(5):389-95. PMC: 4002677. DOI: 10.1038/cmi.2010.28. View

Hemmerich S, Butcher E, Rosen S . Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selectin and MECA 79, and adhesion-blocking monoclonal antibody. J Exp Med. 1994; 180(6):2219-26. PMC: 2191797. DOI: 10.1084/jem.180.6.2219. View

Perrone G, Ruffini P, Catalano V, Spino C, Santini D, Muretto P . Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 2008; 44(13):1875-82. DOI: 10.1016/j.ejca.2008.05.017. View

Hori S, Sakaguchi S . Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 2004; 6(8):745-51. DOI: 10.1016/j.micinf.2004.02.020. View

Lee H, Kim J, Park I, Song I, Yu J, Ahn J . Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. Am J Clin Pathol. 2015; 144(2):278-88. DOI: 10.1309/AJCPIXUYDVZ0RZ3G. View

Heimberger A, Abou-Ghazal M, Reina-Ortiz C, Yang D, Sun W, Qiao W . Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008; 14(16):5166-72. DOI: 10.1158/1078-0432.CCR-08-0320. View

Hiraoka N, Ino Y, Yamazaki-Itoh R . Tertiary Lymphoid Organs in Cancer Tissues. Front Immunol. 2016; 7:244. PMC: 4916185. DOI: 10.3389/fimmu.2016.00244. View

10.

Sakai Y, Hoshino H, Kitazawa R, Kobayashi M . High endothelial venule-like vessels and lymphocyte recruitment in testicular seminoma. Andrology. 2014; 2(2):282-9. DOI: 10.1111/j.2047-2927.2014.00192.x. View

11.

Avram G, Sanchez-Sendra B, Martin J, Terradez L, Ramos D, Monteagudo C . The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma. Histopathology. 2013; 63(6):852-61. DOI: 10.1111/his.12235. View

12.

Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P . High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. Oncoimmunology. 2012; 1(6):829-839. PMC: 3489738. DOI: 10.4161/onci.20492. View

13.

Spiotto M, Yu P, Rowley D, Nishimura M, Meredith S, Gajewski T . Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002; 17(6):737-47. DOI: 10.1016/s1074-7613(02)00480-6. View

14.

Kilinc M, Gu T, Harden J, Virtuoso L, Egilmez N . Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J Immunol. 2009; 182(7):4217-25. DOI: 10.4049/jimmunol.0802793. View

15.

Roybal K, Williams J, Morsut L, Rupp L, Kolinko I, Choe J . Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016; 167(2):419-432.e16. PMC: 5072533. DOI: 10.1016/j.cell.2016.09.011. View

16.

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R . Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018; 6(1):8. PMC: 5778665. DOI: 10.1186/s40425-018-0316-z. View

17.

Hinrichs C, Rosenberg S . Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2013; 257(1):56-71. PMC: 3920180. DOI: 10.1111/imr.12132. View

18.

Klebanoff C, Gattinoni L, Restifo N . CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006; 211:214-24. PMC: 1501075. DOI: 10.1111/j.0105-2896.2006.00391.x. View

19.

Petersen R, Campa M, Sperlazza J, Conlon D, Joshi M, Harpole Jr D . Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006; 107(12):2866-72. DOI: 10.1002/cncr.22282. View

20.

Yu P, Lee Y, Liu W, Chin R, Wang J, Wang Y . Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004; 5(2):141-9. DOI: 10.1038/ni1029. View